Hypothesis\n\nAdministering a senolytic regimen before cyclic OSK expression or chemical reprogramming will increase reprogramming efficiency, reduce tumorigenic risk, and produce greater functional and lifespan benefits than either approach alone.\n\n## Mechanistic Rationale\n\nSenescent cells secrete a pro‑inflammatory SASP (IL‑6, TGF‑β, PAI‑1) that activates STAT3 and SMAD pathways, which inhibit OSK‑driven chromatin opening and promote heterochromatin retention at pluripotency loci [3,4]. Clearing these cells with senolytics such as D+Q or JQ1 lowers SASP burden, reduces DNA damage signaling, and creates a permissive epigenetic environment for OSK‑mediated demethylation of aging-associated sites [5,6]. Moreover, senolytic‑induced reduction of epigenetic age in human blood suggests that senescent cells themselves contribute to age‑related methylation drift; their removal may lower the methylation barrier that reprogramming must overcome [5].\n\nThus, a senolytic pretreatment should: (1) decrease inflammatory signaling that antagonizes OSK activity, (2) lower baseline epigenetic age, and (3) improve the proportion of cells capable of complete reprogramming without incomplete intermediates that raise tumorigenic risk [7], 8].\n\n## Experimental Design\n\nUse 20‑month‑old C57BL/6 mice (n=15 per group). Groups:\n1. Vehicle control\n2. Senolytic only (D+Q 5 mg/kg dasatinib + 50 mg/kg quercetin, i.p., weekly for 3 doses)\n3. Reprogramming only (doxycycline‑inducible OSK, 2 days on/5 days off for 4 cycles)\n4. Senolytic → Reprogramming (same senolytic schedule, start OSK 48 h after last senolytic dose)\n5. Reprogramming → Senolytic (OSK first, senolytic after final OSK cycle)\n6. Concurrent (senolytic and OSK overlapping)\n\nEndpoints (assessed at 4 weeks post‑intervention and at natural death):\n- Epigenetic age of blood and liver (Horvath mouse clock)\n- Flow cytometry for p16^INK4a^+ senescent cells\n- SASP cytokine serum levels (IL‑6, TGF‑β)\n- Global H3K9me3 and H3K27ac ChIP‑seq at OSK target promoters\n- Fraction of cells expressing pluripotency markers (OCT4, NANOG) without DNA damage (γH2AX^-)\n- Frailty index, grip strength, treadmill endurance\n- Tumor palpation and histopathological review\n- Overall survival\n\n## Predicted Outcomes\n\nIf the hypothesis is correct, group 4 (senolytic → reprogramming) will show:\n- Greatest reduction in epigenetic age (≈‑2.5 years vs control)\n- Lowest residual p16^INK4a^+ cells\n- Decreased SASP cytokines\n- Higher OCT4^+/NANOG^+ cells with low γH2AX\n- Improved frailty and physical performance exceeding groups 2 and 3\n- No increase in tumor incidence compared with reprogramming alone\n- Significant lifespan extension (>30 % median survival increase) over controls\n\nConversely, groups 5 and 6 are expected to show intermediate benefits, while senolytic only or reprogramming only will yield modest improvements, confirming that senolytic pretreatment uniquely primes the milieu for safe, effective reprogramming.\n\n## Falsifiability\n\nFailure to observe enhanced epigenetic age reversal, improved functional metrics, or increased reprogramming marker expression in the senolytic → reprogramming group relative to reprogramming alone would falsify the hypothesis. Likewise, a rise in tumor formation in this group would indicate that senolytic pretreatment does not mitigate tumorigenic risk, contradicting the proposed mechanism.
